{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T00:42:52Z","timestamp":1780360972350,"version":"3.54.1"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,6,4]],"date-time":"2025-06-04T00:00:00Z","timestamp":1748995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,6,4]],"date-time":"2025-06-04T00:00:00Z","timestamp":1748995200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"the Basic Medical Health and Technology Project of Wenzhou","award":["No.Y2020944"],"award-info":[{"award-number":["No.Y2020944"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Imaging"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Accurate assessment and prediction of patient prognosis, early identification of high-risk patients, and improvement of clinical outcomes for individuals with extranodal natural killer\/T-cell lymphoma (ENKTCL) are critical. This study evaluates the prognostic value of a novel model combining maximum standardized uptake value (SUVmax) and absolute lymphocyte count (ALC) in ENKTCL patients.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>We conducted a retrospective analysis of clinical data from 57 patients diagnosed with primary ENKTCL. Optimal cut-off values for SUVmax and ALC were determined using receiver operating characteristic (ROC) curves. Clinical characteristics were analyzed by Chi-squared tests or Fisher\u2019s exact tests. Survival analysis was performed using the Kaplan-Meier method and log-rank test, while independent prognostic factors were identified through Cox regression analysis.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>The optimal cut-off values for SUVmax and ALC were established at 11.8 and 0.87\u2009\u00d7\u200910<jats:sup>9<\/jats:sup>\/L, respectively. Univariate and multivariate analyses confirmed that both SUVmax and ALC were independent predictors of prognosis in ENKTCL patients. According to the combined SUVmax-ALC model, the patients were stratified into low-risk, intermediate-risk and high-risk groups. Kaplan-Meier analysis revealed significant differences in overall survival (OS) and progression-free survival (PFS) among these groups (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001). ROC curve analysis showed that the area under the curve (AUC) for the SUVmax-ALC model was 0.714, superior to individual tests (SUVmax, AUC\u2009=\u20090.674; ALC, AUC\u2009=\u20090.589). In addition, the AUC of the SUVmax-ALC model was higher than the International Prognostic Index (IPI, AUC\u2009=\u20090.632), nomogram-revised risk index (NRI, AUC\u2009=\u20090.566), and prognostic index of natural killer T-cell lymphoma (PINK, AUC\u2009=\u20090.592). Furthermore, the SUVmax-ALC model more effectively identified high-risk patients within low-risk IPI, PINK, or NRI groups, providing additional prognostic information. These findings indicate that the combination of SUVmax and ALC offers enhanced predictive accuracy for ENKTCL prognosis.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>Pre-treatment SUVmax and ALC can serve as valuable indicators for predicting the prognosis of ENKTCL patients. Compared to IPI, NRI, and PINK scores, the SUVmax-ALC model demonstrates superior performance in risk stratification, suggesting its potential as an effective personalized prognostic tool for ENKTCL patients.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/s40644-025-00882-0","type":"journal-article","created":{"date-parts":[[2025,6,4]],"date-time":"2025-06-04T19:32:35Z","timestamp":1749065555000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Prognostic value of the pre-treatment SUVmax of 18F-FDG PET\/CT combined with peripheral absolute lymphocyte in patients with newly diagnosed extranodal natural killer\/T-cell lymphoma"],"prefix":"10.1186","volume":"25","author":[{"given":"Xingmei","family":"Lu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kate","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yida","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiuhuan","family":"Ji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suidan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianmin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,6,4]]},"reference":[{"key":"882_CR1","doi-asserted-by":"publisher","first-page":"2460","DOI":"10.1038\/s41375-021-01313-2","volume":"35","author":"H Wang","year":"2021","unstructured":"Wang H, Fu BB, Gale RP, Liang Y. NK-\/T-cell lymphomas. Leukemia. 2021;35:2460\u20138.","journal-title":"Leukemia"},{"key":"882_CR2","doi-asserted-by":"publisher","first-page":"1720","DOI":"10.1038\/s41375-022-01620-2","volume":"36","author":"R Alaggio","year":"2022","unstructured":"Alaggio R, Amador C, Anagnostopoulos I, Attygalle AD, Araujo IBO, Berti E, et al. The 5th edition of the world health organization classification of haematolymphoid tumours: lymphoid neoplasms. Leukemia. 2022;36:1720\u201348.","journal-title":"Leukemia"},{"key":"882_CR3","doi-asserted-by":"publisher","first-page":"4997","DOI":"10.1182\/blood-2013-01-453233","volume":"121","author":"E Tse","year":"2013","unstructured":"Tse E, Kwong YL. How I treat NK\/T-cell lymphomas. Blood. 2013;121:4997\u20135005.","journal-title":"Blood"},{"key":"882_CR4","first-page":"7141","volume":"16","author":"Y Harabuchi","year":"2019","unstructured":"Harabuchi Y, Takahara M, Kishibe K, Nagato T, Kumai T. Extranodal natural killer\/T-cell lymphoma, nasal type: basic science and clinical progress. Front Pediatr. 2019;16:7141.","journal-title":"Front Pediatr"},{"key":"882_CR5","doi-asserted-by":"publisher","first-page":"285","DOI":"10.6004\/jnccn.2022.0015","volume":"20","author":"SM Horwitz","year":"2022","unstructured":"Horwitz SM, Ansell S, Ai WZ, Barnes J, Barta SK, Brammer J, et al. T-cell lymphomas, version 2.2022, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2022;20:285\u2013308.","journal-title":"J Natl Compr Canc Netw"},{"issue":"3","key":"882_CR6","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1016\/j.beha.2019.06.005","volume":"32","author":"E Tse","year":"2019","unstructured":"Tse E, Kwong YL. NK\/T-cell lymphomas. Best Pract Res Clin Haematol. 2019;32(3):253\u201361.","journal-title":"Best Pract Res Clin Haematol"},{"key":"882_CR7","doi-asserted-by":"publisher","first-page":"1895","DOI":"10.1007\/s00277-014-2137-6","volume":"93","author":"SJ Kim","year":"2014","unstructured":"Kim SJ, Yang D-H, Kim JS, Kwak J-Y, Eom H-S, Hong DS, et al. Concurrent chemoradiotherapy followed by l-asparaginase-containing chemotherapy, VIDL, for localized nasal extranodal NK\/T cell lymphoma: CISL08-01 phase II study. Ann Hematol. 2014;93:1895\u2013901.","journal-title":"Ann Hematol"},{"key":"882_CR8","doi-asserted-by":"publisher","first-page":"4410","DOI":"10.1200\/JCO.2011.35.6287","volume":"29","author":"M Yamaguchi","year":"2011","unstructured":"Yamaguchi M, Kwong Y-L, Kim WS, Maeda Y, Hashimoto C, Suh C, et al. Phase II study of SMILE chemotherapy for newly diagnosed stage IV, relapsed, or refractory extranodal natural killer (NK)\/T-cell lymphoma, nasal type: the NK-cell tumor study group study. JCO. 2011;29:4410\u20136.","journal-title":"JCO"},{"key":"882_CR9","doi-asserted-by":"publisher","first-page":"3548","DOI":"10.3390\/cancers12123548","volume":"12","author":"KJ Ryu","year":"2020","unstructured":"Ryu KJ, Lee JY, Choi ME, Yoon SE, Cho J, Ko YH, et al. Serumderived exosomal MicroRNA profiles can predict poor survival outcomes in patients with extranodal natural killer\/T-cell lymphoma. Cancers (Basel). 2020;12:3548.","journal-title":"Cancers (Basel)"},{"issue":"4","key":"882_CR10","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1200\/JCO.2005.04.1384","volume":"24","author":"J Lee","year":"2006","unstructured":"Lee J, Suh C, Park YH, Ko YH, Bang SM, Lee JH, et al. Extranodal natural killer T-cell lymphoma, nasal-type: a prognostic model from a retrospective multicenter study. J Clin Oncol. 2006;24(4):612\u20138.","journal-title":"J Clin Oncol"},{"key":"882_CR11","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1016\/S1470-2045(15)00533-1","volume":"17","author":"SJ Kim","year":"2016","unstructured":"Kim SJ, Yoon DH, Jaccard A, Chng WJ, Lim ST, Hong H, et al. A prognostic index for natural killer cell lymphoma after non-anthracycline-based treatment: a multicentre, retrospective analysis. Lancet Oncol. 2016;17:389\u2013400.","journal-title":"Lancet Oncol"},{"key":"882_CR12","doi-asserted-by":"publisher","first-page":"2183","DOI":"10.1007\/s12032-011-0030-x","volume":"29","author":"JJ Huang","year":"2012","unstructured":"Huang JJ, Zhu YJ, Xia Y, Zhao W, Lin TY, Jiang WQ, et al. A novel prognostic model for extranodal natural killer\/T-cell lymphoma. Med Oncol. 2012;29:2183\u201390.","journal-title":"Med Oncol"},{"key":"882_CR13","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1038\/s41375-020-0791-3","volume":"35","author":"SY Chen","year":"2021","unstructured":"Chen SY, Yang Y, Qi SN, Wang Y, Hu C, He X, et al. Validation of nomogram-revised risk index and comparison with other models for extranodal nasal-type NK\/T-cell lymphoma in the modern chemotherapy era: indication for prognostication and clinical decision-making. Leukemia. 2021;35:130\u201342.","journal-title":"Leukemia"},{"key":"882_CR14","doi-asserted-by":"publisher","first-page":"755","DOI":"10.6004\/jnccn.2020.0026","volume":"18","author":"RT Hoppe","year":"2020","unstructured":"Hoppe RT, Advani RH, Ai WZ, Ambinder RF, Armand P, Bello CM, et al. Hodgkin lymphoma, version 2.2020, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2020;18:755\u201381.","journal-title":"J Natl Compr Canc Netw"},{"key":"882_CR15","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1007\/s11912-021-01127-6","volume":"23","author":"BD Cheson","year":"2021","unstructured":"Cheson BD, Meignan M. Current role of functional imaging in the management of lymphoma. Curr Oncol Rep. 2021;23:144.","journal-title":"Curr Oncol Rep"},{"key":"882_CR16","doi-asserted-by":"publisher","first-page":"1626","DOI":"10.2967\/jnumed.107.042093","volume":"48","author":"C Lin","year":"2007","unstructured":"Lin C, Itti E, Haioun C, Petegnief Y, Luciani A, Dupuis J, et al. Early 18F-FDG PET for prediction of prognosis in patients with diffuse large B-cell lymphoma: SUV-based assessment versus visual analysis. J Nucl Med. 2007;48:1626\u201332.","journal-title":"J Nucl Med"},{"key":"882_CR17","doi-asserted-by":"publisher","first-page":"e22143","DOI":"10.1097\/MD.0000000000022143","volume":"99","author":"XW Xia","year":"2020","unstructured":"Xia XW, Wang YQ, Yuan JJ, Sun WJ, Jiang JJ, Liu C, et al. Baseline SUVmax of 18F-FDG PET-CT indicates prognosis of extranodal natural killer\/T-cell lymphoma. Med (Baltim). 2020;99:e22143.","journal-title":"Med (Baltim)"},{"key":"882_CR18","doi-asserted-by":"publisher","first-page":"41057","DOI":"10.1038\/srep41057","volume":"7","author":"Y Chang","year":"2017","unstructured":"Chang Y, Fu X, Sun Z, Xie X, Wang R, Li Z, et al. Utility of baseline, interim and end-of-treatment (18)F-FDG PET\/CT in extranodal natural killer\/T-cell lymphoma patients treated with L-asparaginase\/pegaspargase. Sci Rep. 2017;7:41057.","journal-title":"Sci Rep"},{"key":"882_CR19","doi-asserted-by":"publisher","first-page":"e0194435","DOI":"10.1371\/journal.pone.0194435","volume":"13","author":"H Wang","year":"2018","unstructured":"Wang H, Shen G, Jiang C, Li L, Cui F, Tian R. Prognostic value of baseline, interim and end of-treatment 18F-FDG PET\/CT parameters in extranodal natural killer\/T-cell lymphoma: a meta-analysis. PLoS ONE. 2018;13:e0194435.","journal-title":"PLoS ONE"},{"key":"882_CR20","doi-asserted-by":"publisher","first-page":"1783","DOI":"10.2967\/jnumed.108.053355","volume":"49","author":"C Suh","year":"2008","unstructured":"Suh C, Kang YK, Roh JL, Kim MR, Kim JS, Huh J, et al. Prognostic value of tumor 18F-FDG uptake in patients with untreated extranodal natural killer\/T-cell lymphomas of the head and neck. J Nucl Med. 2008;49:1783\u20139.","journal-title":"J Nucl Med"},{"key":"882_CR21","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1007\/s12032-012-0339-0","volume":"30","author":"B Bai","year":"2013","unstructured":"Bai B, Huang HQ, Cai QC, Fan W, Wang XX, Zhang X, et al. Predictive value of pretreatment positron emission tomography\/computed tomography in patients with newly diagnosed extranodal natural killer\/T-cell lymphoma. Med Oncol. 2013;30:339.","journal-title":"Med Oncol"},{"key":"882_CR22","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.1007\/s00259-013-2443-6","volume":"40","author":"CY Kim","year":"2013","unstructured":"Kim CY, Hong CM, Kim DH, Son SH, Jeong SY, Lee SW, et al. Prognostic value of whole-body metabolic tumour volume and total lesion glycolysis measured on 18F-FDG PET\/CT in patients with extranodal NK\/T-cell lymphoma. Eur J Nucl Med Mol Imaging. 2013;40:1321\u20139.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"882_CR23","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/s40644-020-00379-y","volume":"21","author":"H Li","year":"2021","unstructured":"Li H, Shao G, Zhang Y, Chen X, Du C, Wang K, et al. Nomograms based on SUVmax of 18F-FDG PET\/CT and clinical parameters for predicting progression-free and overall survival in patients with newly diagnosed extranodal natural killer\/T-cell lymphoma. Cancer Imaging. 2021;21:9.","journal-title":"Cancer Imaging"},{"key":"882_CR24","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1016\/j.blre.2008.03.009","volume":"22","author":"H Tran","year":"2008","unstructured":"Tran H, Nourse J, Hall S, Green M, Griffiths L, Gandhi MK. Immunodeficiency-associated lymphomas. Blood Rev. 2008;22:261\u201381.","journal-title":"Blood Rev"},{"key":"882_CR25","doi-asserted-by":"publisher","first-page":"2227","DOI":"10.1038\/sj.leu.2404780","volume":"21","author":"DH Kim","year":"2007","unstructured":"Kim DH, Baek JH, Chae YS, Kim YK, Kim HJ, Park YH, et al. Absolute lymphocyte counts predicts response to chemotherapy and survival in diffuse large B-cell lymphoma. Leukemia. 2007;21:2227\u201330.","journal-title":"Leukemia"},{"key":"882_CR26","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1093\/annonc\/mdq314","volume":"22","author":"JJ Huang","year":"2011","unstructured":"Huang JJ, Jiang WQ, Lin TY, Huang Y, Xu RH, Huang HQ, et al. Absolute lymphocyte count is a novel prognostic indicator in extranodal natural killer\/T-cell lymphoma, nasal type. Ann Oncol. 2011;22:149\u201355.","journal-title":"Ann Oncol"},{"key":"882_CR27","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1002\/ajh.25878","volume":"95","author":"SN Qi","year":"2020","unstructured":"Qi SN, Yang Y, Zhang YJ, Huang HQ, Wang Y, He X, et al. Risk-based, response-adapted therapy for early-stage extranodal nasal-type NK\/T-cell lymphoma in the modern chemotherapy era: a China lymphoma collaborative group (CLCG) study. Am J Hematol. 2020;95:1047\u201356.","journal-title":"Am J Hematol"},{"key":"882_CR28","doi-asserted-by":"publisher","first-page":"4124","DOI":"10.1200\/JCO.2008.16.4558","volume":"26","author":"J Vose","year":"2008","unstructured":"Vose J, Armitage J, Weisenburger D, International TCLP. International peripheral T-cell and natural killer\/T-cell lymphoma study: pathology findings and clinical outcomes. J Clin Oncol. 2008;26:4124\u201330.","journal-title":"J Clin Oncol"},{"key":"882_CR29","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1186\/s13045-017-0452-9","volume":"10","author":"E Tse","year":"2017","unstructured":"Tse E, Kwong YL. The diagnosis and management of NK\/T-cell lymphomas. J Hematol Oncol. 2017;10:85.","journal-title":"J Hematol Oncol"},{"key":"882_CR30","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1080\/17474086.2016.1206465","volume":"9","author":"E Tse","year":"2016","unstructured":"Tse E, Kwong YL. Diagnosis and management of extranodal NK\/T cell lymphoma nasal type. Expert Rev Hematol. 2016;9:861\u201371.","journal-title":"Expert Rev Hematol"},{"key":"882_CR31","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1093\/annonc\/mdi037","volume":"16","author":"WY Au","year":"2005","unstructured":"Au WY, Ma SY, Chim CS, Choy C, Loong F, Lie AK, et al. Clinicopathologic features and treatment outcome of mature T-cell and natural killer-cell lymphomas diagnosed according to the world health organization classification scheme: a single center experience of 10 years. Ann Oncol. 2005;16:206\u201314.","journal-title":"Ann Oncol"},{"key":"882_CR32","doi-asserted-by":"publisher","first-page":"e258","DOI":"10.1097\/MD.0000000000000258","volume":"93","author":"XX Zhou","year":"2014","unstructured":"Zhou XX, Lu K, Geng LY, Li XY, Jiang YJ, Wang X. Utility of PET\/CT in the diagnosis and staging of extranodal natural killer\/T-cell lymphoma: a systematic review and meta-analysis. Med (Baltim). 2014;93:e258.","journal-title":"Med (Baltim)"},{"key":"882_CR33","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1007\/s12032-014-0218-y","volume":"31","author":"L Jiang","year":"2014","unstructured":"Jiang L, Li P, Wang H, Liu J, Zhang X, Qiu H, et al. Prognostic significance of Ki-67 antigen expression in extranodal natural killer\/T-cell lymphoma, nasal type. Med Oncol. 2014;31:218.","journal-title":"Med Oncol"},{"key":"882_CR34","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1007\/s12094-023-03238-x","volume":"26","author":"XH Liu","year":"2024","unstructured":"Liu XH, Cao DD, Liu H, Ke XK, Liu X, Xu XM. Comparative analysis of upper aerodigestive tract and non-upper aerodigestive tract in NK\/T cell lymphoma. Clin Transl Oncol. 2024;26:214\u201324.","journal-title":"Clin Transl Oncol"},{"key":"882_CR35","doi-asserted-by":"crossref","unstructured":"Barrington SF, George Mikhaeel N, Kostakoglu L, Meignan M, Hutchings M et al. Role of imaging in the staging and response assessment of lymphoma: consensus of the International Conference on Malignant Lymphomas Imaging Working Group. J Clin Oncol. 2014;32:3048-58.","DOI":"10.1200\/JCO.2013.53.5229"}],"container-title":["Cancer Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40644-025-00882-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40644-025-00882-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40644-025-00882-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,4]],"date-time":"2025-06-04T19:32:36Z","timestamp":1749065556000},"score":1,"resource":{"primary":{"URL":"https:\/\/cancerimagingjournal.biomedcentral.com\/articles\/10.1186\/s40644-025-00882-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,4]]},"references-count":35,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["882"],"URL":"https:\/\/doi.org\/10.1186\/s40644-025-00882-0","relation":{},"ISSN":["1470-7330"],"issn-type":[{"value":"1470-7330","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,4]]},"assertion":[{"value":"23 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 June 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was authorized by the Ethics Committee for Clinical Research (ECCR) of the First Affiliated Hospital of Wenzhou Medical University. The ECCR waived this retrospective study informed consent (No. KY2021-R081).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All authors consent to the publication of this manuscript.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"67"}}